Atrial fibrillation (AF) is the leading preventable cause of ischemic stroke and is associated with higher mortality when compared with stroke in non-AF patients. Although oral anticoagulants are the standard therapeutic approach for stroke prevention in AF patients, many patients are unable to utilize these medications. Percutaneous left atrial appendage closure (LAAC) provides a non-pharmacologic alternative approach for stroke prevention. LAAC is a safe procedure that may be performed with a same-discharge strategy. The WATCHMAN and Amulet devices have been used for stroke prevention in patients with nonvalvular atrial fibrillation (NVAF) who have an appropriate rationale to seek an alternative to oral anticoagulation. Many randomized trials and multicenter registries over the past decade have supported the clinical use of LAAC, especially for those devices. Increased operator experience and widespread adoption of LAAC implantation techniques have seen improvements in safety, procedural, and clinical outcomes. It is important to highlight that the data available from randomized clinical trials (RCT) involved earlier generation devices with less evolved implantation techniques. In addition, the patients of subsequent registry analyses often have more comorbidities than these landmark trials, and yet devices demonstrate superior safety and performance outcomes. The currently approved LAAC devices offer significant improvements compared to its predecessors and provide an excellent option for LAAC procedure.